Compare · BIS vs HCXY
BIS vs HCXY
Side-by-side comparison of ProShares UltraShort Nasdaq Biotechnology (BIS) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIS and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.53B.
- Over the past year, BIS is down 52.1% and HCXY is down 0.5% - HCXY leads by 51.6 points.
ProShares UltraShort Nasdaq Biotechnology
The investment seeks daily investment results that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Latest BIS
Latest HCXY
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call
- Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments
- Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS
- Hercules Capital Named 2025 Americas BDC Manager of the Year by Private Debt Investor
- Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results
- Hercules Capital Closes Institutional Notes Offering of $300.0 Million 5.350% Unsecured Notes due 2029